Regeneron Pharmaceuticals (REGN) Other Non-Current Liabilities (2009 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Other Non-Current Liabilities of $2.3 billion for Q2 2026, up 34.06% year-over-year from $1.7 billion in Q2 2025, and up 7.31% quarter-over-quarter from $2.1 billion in Q1 2026.
Regeneron Pharmaceuticals (REGN) Other Non-Current Liabilities (2009 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Other Non-Current Liabilities history runs 18 years deep, the most recent figure standing at $2.3 billion for Q2 2026.
- In Q2 2026, Other Non-Current Liabilities rose 34.06% year-over-year to $2.3 billion; the TTM figure through Jun 2026 stood at $2.3 billion (up 34.06% YoY), while the FY2025 annual figure was $2.0 billion, up 28.47% from the prior year.
- Other Non-Current Liabilities for Q2 2026 stood at $2.3 billion, up from $2.1 billion in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $2.3 billion in Q2 2026, with the low at $43.7 million in Q3 2023.
- The 5-year median for Other Non-Current Liabilities is $1.2 billion (2024), against an average of $1.2 billion.
- The sharpest annual moves came in 2023 and 2024: Other Non-Current Liabilities sank 92.7% in 2023, then soared 3432.27% in 2024.
- Regeneron Pharmaceuticals' Other Non-Current Liabilities stood at $638.0 million in 2022, then soared by 33.87% to $854.1 million in 2023, then soared by 83.98% to $1.6 billion in 2024, then rose by 28.47% to $2.0 billion in 2025, then rose by 13.02% to $2.3 billion in 2026.
- Business Quant data shows REGN's Other Non-Current Liabilities at $2.3 billion in Q2 2026, $2.1 billion in Q1 2026, and $2.0 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.28 Bn |
| Mar 31, 2026 | 2.13 Bn |
| Dec 31, 2025 | 2.02 Bn |
| Sep 30, 2025 | 1.86 Bn |
| Jun 30, 2025 | 1.70 Bn |
| Mar 31, 2025 | 1.67 Bn |
| Dec 31, 2024 | 1.57 Bn |
| Sep 30, 2024 | 1.54 Bn |
| Jun 30, 2024 | 1.46 Bn |
| Mar 31, 2024 | 908.50 Mn |
| Dec 31, 2023 | 854.10 Mn |
| Sep 30, 2023 | 43.70 Mn |
| Jun 30, 2023 | 716.80 Mn |
| Mar 31, 2023 | 677.30 Mn |
| Dec 31, 2022 | 638.00 Mn |
| Sep 30, 2022 | 598.60 Mn |
| Jun 30, 2022 | 724.70 Mn |
| Mar 31, 2022 | 692.50 Mn |
| Dec 31, 2021 | 680.20 Mn |
| Sep 30, 2021 | 662.60 Mn |